These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 30098724)

  • 1. The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond.
    Sorbye H; Baudin E; Perren A
    Endocrinol Metab Clin North Am; 2018 Sep; 47(3):683-698. PubMed ID: 30098724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastroenteropancreatic high-grade neuroendocrine carcinoma.
    Sorbye H; Strosberg J; Baudin E; Klimstra DS; Yao JC
    Cancer; 2014 Sep; 120(18):2814-23. PubMed ID: 24771552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.
    Klöppel G
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
    Janson ET; Sorbye H; Welin S; Federspiel B; Grønbæk H; Hellman P; Ladekarl M; Langer SW; Mortensen J; Schalin-Jäntti C; Sundin A; Sundlöv A; Thiis-Evensen E; Knigge U
    Acta Oncol; 2014 Oct; 53(10):1284-97. PubMed ID: 25140861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the cytologic diagnosis of gastroenteropancreatic neuroendocrine neoplasms.
    Sigel CS
    Cancer Cytopathol; 2018 Dec; 126(12):980-991. PubMed ID: 30485690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
    Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P
    Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology.
    Crippa S; Partelli S; Belfiori G; Palucci M; Muffatti F; Adamenko O; Cardinali L; Doglioni C; Zamboni G; Falconi M
    World J Gastroenterol; 2016 Dec; 22(45):9944-9953. PubMed ID: 28018101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma.
    Thomas KEH; Voros BA; Boudreaux JP; Thiagarajan R; Woltering EA; Ramirez RA
    Oncologist; 2019 Aug; 24(8):1076-1088. PubMed ID: 30635447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of metastatic disease in patients with neuroendocrine tumors.
    Niederhuber JE; Fojo T
    Surg Oncol Clin N Am; 2006 Jul; 15(3):511-33, viii. PubMed ID: 16882495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
    Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
    Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3).
    Sorbye H; Baudin E; Borbath I; Caplin M; Chen J; Cwikla JB; Frilling A; Grossman A; Kaltsas G; Scarpa A; Welin S; Garcia-Carbonero R;
    Neuroendocrinology; 2019; 108(1):54-62. PubMed ID: 30153658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.
    Garcia-Carbonero R; Sorbye H; Baudin E; Raymond E; Wiedenmann B; Niederle B; Sedlackova E; Toumpanakis C; Anlauf M; Cwikla JB; Caplin M; O'Toole D; Perren A;
    Neuroendocrinology; 2016; 103(2):186-94. PubMed ID: 26731334
    [No Abstract]   [Full Text] [Related]  

  • 14. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors.
    Shida T; Kishimoto T; Furuya M; Nikaido T; Koda K; Takano S; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Tanizawa T; Nakatani Y; Miyazaki M
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):889-93. PubMed ID: 19657638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastroenteropancreatic neuroendocrine neoplasms: selected pathology review and molecular updates.
    Chai SM; Brown IS; Kumarasinghe MP
    Histopathology; 2018 Jan; 72(1):153-167. PubMed ID: 29239038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up.
    Oberg K; Jelic S;
    Ann Oncol; 2008 May; 19 Suppl 2():ii104-5. PubMed ID: 18456741
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastroenteropancreatic neuroendocrine tumors. Where are we now?
    Castellano D
    Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():1. PubMed ID: 21365184
    [No Abstract]   [Full Text] [Related]  

  • 19. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
    Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
    Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.
    Kulke MH; Anthony LB; Bushnell DL; de Herder WW; Goldsmith SJ; Klimstra DS; Marx SJ; Pasieka JL; Pommier RF; Yao JC; Jensen RT;
    Pancreas; 2010 Aug; 39(6):735-52. PubMed ID: 20664472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.